PMID- 34853221
OWN - NLM
STAT- MEDLINE
DCOM- 20211213
LR  - 20211214
IS  - 1349-3299 (Electronic)
IS  - 1349-2365 (Linking)
VI  - 62
IP  - 6
DP  - 2021
TI  - Prevalence, Characteristics, and Impact of Frailty in Patients with Functional 
      Tricuspid Regurgitation.
PG  - 1280-1286
LID - 10.1536/ihj.21-273 [doi]
AB  - Little is known as regards frailty in patients with functional tricuspid 
      regurgitation (FTR). Thus, in this study, we aimed to investigate the prevalence, 
      characteristics, and impact of frailty on patients with severe FTR.This 
      prospective study included 110 consecutive patients with severe FTR who were 
      assessed via transthoracic echocardiography at an outpatient clinic. Patients 
      were dichotomized using short physical performance battery (SPPB). To better 
      understand the whole picture of frailty in patients with FTR, other frailty 
      scales were also assessed (frailty checklist, clinical frailty scale, gait speed, 
      and Columbia frailty scale). The primary endpoint was the combination of 
      all-cause mortality and heart failure hospitalization.According to each 
      definition of frailty, 28%-46% were identified to be frail. Those with SPPB score 
      of < 9 were older, had greater New York Heart Association (NYHA) functional 
      classification, and had lower albumin level and estimated glomerular filtration 
      rate compared with those with SPPB score of >/= 9. They also have smaller tricuspid 
      valve coaptation depth and worse right ventricular fractional area change 
      (RV-FAC) than those with SPPB score of >/= 9 despite having similar TR severity. 
      The primary endpoint at 1 year was noted in 31% of patients. The SPPB score has 
      excellent discriminatory performance for predicting the primary endpoint (area 
      under the curve 0.82, 95% confidence interval [CI] 0.76-0.91) in receiver 
      operating characteristic analysis and was independently associated with the 
      primary endpoint after adjustment in multivariate analysis (adjusted hazard ratio 
      0.81, 95% CI, 0.73-0.90; P < 0.001).Frailty has been widely prevalent in the 
      elderly patient population with FTR; in fact, it has been determined to be strong 
      parameter for poor outcomes.
FAU - Saji, Mike
AU  - Saji M
AD  - Department of Cardiology, Sakakibara Heart Institute.
AD  - Department of Cardiology, Keio University School of Medicine.
FAU - Yoshikawa, Tsutomu
AU  - Yoshikawa T
AD  - Department of Cardiology, Sakakibara Heart Institute.
AD  - Department of Cardiology, Keio University School of Medicine.
FAU - Takayama, Morimasa
AU  - Takayama M
AD  - Department of Cardiology, Sakakibara Heart Institute.
FAU - Izumi, Yuki
AU  - Izumi Y
AD  - Department of Cardiology, Sakakibara Heart Institute.
FAU - Takamisawa, Itaru
AU  - Takamisawa I
AD  - Department of Cardiology, Sakakibara Heart Institute.
FAU - Okamura, Tomonori
AU  - Okamura T
AD  - Department of Preventive Medicine and Public Health, Keio University School of 
      Medicine.
FAU - Shimizu, Hideyuki
AU  - Shimizu H
AD  - Department of Cardiothoracic Surgery, Keio University School of Medicine.
FAU - Lim, David Scott
AU  - Lim DS
AD  - Advanced Cardiac Valve Center, Department of Medicine, Division of Cardiovascular 
      Medicine, University of Virginia.
FAU - Latib, Azeem
AU  - Latib A
AD  - Department of Cardiology, Montefiore Medical Center.
FAU - Isobe, Mitsuaki
AU  - Isobe M
AD  - Department of Cardiology, Sakakibara Heart Institute.
FAU - Fukuda, Keiichi
AU  - Fukuda K
AD  - Department of Cardiology, Keio University School of Medicine.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Int Heart J
JT  - International heart journal
JID - 101244240
RN  - 0 (Serum Albumin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Frailty/diagnosis/*epidemiology
MH  - Geriatric Assessment
MH  - Glomerular Filtration Rate
MH  - Heart Failure/epidemiology
MH  - Hospitalization
MH  - Humans
MH  - Japan/epidemiology
MH  - Male
MH  - Prevalence
MH  - Prospective Studies
MH  - Serum Albumin/analysis
MH  - Tricuspid Valve Insufficiency/*epidemiology
OTO - NOTNLM
OT  - All-cause mortality
EDAT- 2021/12/03 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/12/02 05:56
PHST- 2021/12/02 05:56 [entrez]
PHST- 2021/12/03 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - 10.1536/ihj.21-273 [doi]
PST - ppublish
SO  - Int Heart J. 2021;62(6):1280-1286. doi: 10.1536/ihj.21-273.